<DOC>
	<DOC>NCT01853982</DOC>
	<brief_summary>This is a Phase 3, multicenter, prospective, randomized, open-label, study to compare the safety and efficacy of intravenous (IV) ceftolozane/tazobactam with that of IV piperacillin/tazobactam in the treatment of ventilator-associated pneumonia (VAP) in adult participants .</brief_summary>
	<brief_title>Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Cephalosporins</mesh_term>
	<mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
	<mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
	<criteria>Key Participant has received mechanical ventilation for &gt; 48 hours Acute Physiology and Chronic Health Evaluation (APACHE) II score of 1135 Presence of a new or progressive infiltrate on chest xray Presence of clinical criteria consistent with VAP Key History of moderate or severe hypersensitivity reactions to betalactam antibiotics Known end stage renal disease or requirement for dialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>